Immuno-oncology
Immuno-oncology: Harnessing the Immune System to Fight Cancer
What is Immuno-oncology?
Immuno-oncology (I-O) is a field of cancer research and treatment focused on leveraging the body’s own immune system to recognize, target, and destroy cancer cells27. Unlike traditional therapies such as chemotherapy and radiation, which directly target tumor cells, immuno-oncology seeks to empower or re-educate the immune system to mount a more effective anti-tumor response.
How the Immune System Fights Cancer
The immune system protects the body from infections and abnormal cells through two main arms:
- Innate immunity: The body’s first line of defense, providing immediate but non-specific protection (e.g., natural killer (NK) cells, macrophages).
- Adaptive immunity: A more targeted response that develops after exposure to specific antigens, involving T cells and B cells21.
Key immune cells involved in anti-tumor activity include:
- NK cells: Recognize and kill abnormal cells directly or via antibody-dependent cellular cytotoxicity.
- Dendritic cells: Process and present tumor antigens to T cells, initiating adaptive responses.
- CD8+ T cells: Directly kill tumor cells and secrete cytokines like IFN-γ to inhibit tumor growth.
- CD4+ T cells: Help coordinate the immune response and support CD8+ T cell and B cell functions1.
Cancer Immunoediting and Tumor Microenvironment
Cancer progression is shaped by a dynamic interaction between tumor cells and the immune system, a process known as cancer immunoediting. This involves:
- Elimination: Immune cells recognize and destroy emerging tumor cells.
- Equilibrium: Surviving cancer cells are held in check by the immune system, leading to a state of dormancy.
- Escape: Some tumor cells evade immune detection or suppress immune responses, leading to tumor growth17.
The tumor microenvironment (TME) is a complex ecosystem of cancer cells, immune cells, stromal cells, and signaling molecules. The TME can either support anti-tumor immunity or foster immune evasion and tumor progression7.
Types of Immuno-oncology Therapies
Several immunotherapy strategies are used or under development:
- Immune checkpoint inhibitors: Drugs (e.g., pembrolizumab, nivolumab) that block inhibitory pathways (such as PD-1/PD-L1, CTLA-4) to unleash T cells against cancer357.
- CAR-T cell therapy: Patient’s T cells are engineered to better recognize and kill tumor cells, then reinfused357.
- Monoclonal antibodies: Lab-made antibodies that bind to cancer cell targets, marking them for immune destruction3.
- Cancer vaccines: Stimulate the immune system to recognize tumor-specific antigens35.
- Cytokine therapy: Uses immune-modulating proteins (e.g., interleukins, interferons) to boost anti-tumor responses3.
- Immune system modulators: Agents that enhance the body’s overall immune response to cancer3.
Recent Advances and Challenges
- Personalized medicine: Biomarkers (e.g., tumor mutational burden, microsatellite instability) are increasingly used to tailor immunotherapies to individual patients76.
- Combination therapies: Pairing immunotherapies with each other or with chemotherapy/radiation to improve outcomes56.
- Tumor heterogeneity and resistance: Tumors can evolve to evade immune attack, requiring ongoing research into new targets and strategies67.
- Clinical trial innovation: New trial designs and preclinical models are accelerating the development of next-generation immunotherapies46.
Conclusion
Immuno-oncology represents a paradigm shift in cancer treatment, offering durable responses and improved survival for some patients. As our understanding of tumor immunology and the tumor microenvironment deepens, immuno-oncology continues to drive innovation in personalized and more effective cancer therapies576.
Consult with Our Team of Experts Now!
At DrStemCellsThailand (DRSCT)‘s Anti-Aging and Regenerative Medicine Center of Thailand, we emphasize comprehensive evaluations and personalized treatment plans of Cellular Therapy and Stem Cells for managing various health conditions. If you have questions about Immuno-oncology or would like more information on our services, consult with our experts today!
Consult with Our Team of Experts Now!
References:
1. Title: Immuno-oncology: The current landscape and future directions
DOI: 10.1038/s41568-023-00636-6
Summary: This review provides a comprehensive overview of immuno-oncology, including the mechanisms by which the immune system targets cancer, the role of the tumor microenvironment, and advances in checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines. It also discusses challenges such as tumor heterogeneity, resistance, and the integration of biomarkers and personalized medicine in immunotherapy.
2. Title: Recent advances in immuno-oncology: from immune checkpoint blockade to novel cellular therapies
DOI: 10.1016/j.cell.2023.01.025
Summary: This article highlights recent breakthroughs in immuno-oncology, including immune checkpoint inhibitors, CAR-T cell therapies, and the development of personalized cancer vaccines. It emphasizes the importance of understanding immune escape mechanisms and the tumor microenvironment to improve therapeutic outcomes.
3. Title: Personalized immuno-oncology: Biomarkers and combination strategies
DOI: 10.1016/j.immuni.2024.01.006
Summary: Focuses on the use of biomarkers and combination therapies in immuno-oncology, describing how advances in molecular profiling and immune monitoring are driving personalized treatment strategies and overcoming resistance in cancer immunotherapy.
